Nuwellis enters non-binding LOI to acquire Rendiatech, an Israeli renal monitoring firm

Nuwellis, Inc.

Rendiatech specializes in real-time urine flow and acute kidney injury monitoring technologies.
Acquisition intended to expand Nuwellis' platform beyond ultrafiltration into continuous renal health monitoring.
Parties in due diligence; transaction expected to close in Q4 2025, pending board approval and conditions.
No financial terms disclosed in the non-binding letter of intent.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.